Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dabogratinib (TYRA-300) in Low Grade Upper Tract Urothelial Carcinoma (SURF303)
2025-523539-20-00Phase 2Authorised
- Sponsor
- Tyra Biosciences
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, open-label, single-arm trial of dabogratinib in transitional cell carcinoma (TCC), sponsored by Tyra Biosciences. Primary endpoints: Phase 2A complete response within 6 months, Recommended Phase 2B dose determination and 1 more. Planned start Jul 2026; status: authorised.
02
Drugs
dabogratinib
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on 2025-523539-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523539-20-00.